Autism Spectrum Disorder
Conditions
Interventions
Tipepidine Hibenzate (30mg/day, 4weeks)
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.diagnosis of ASD in accordance with the criteria in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) 2.Patients not being treated or taking atypical antipsychotics (risperidone, olanzapine, quetiapine, perospirone, aripiprazole, blonanserin, paliperidone), atomoxetine, methylphenidate, carbamazepine, sodium valproate, gabapentin, topiramate, lamotrigine are eligible 3.The dose of the concomitant drugs has been fixed for at least 4 weeks prior to entry 3.Patients are stable for 4-weeks for medication.
Exclusion criteria
Exclusion criteria: 1.Patients with a previous hypersensitivity to Tipepidine Hibenzate. 2.Patients treated with typical antipsychotics and selective norepinephrine reuptake inhibitor (NRI) except atomoxetine and stimulants except methylphenidate. 3.Pregnant or breast-feeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) [Time Frame: Changes from baseline in CY-BOCS at 4-weeks ] | — |
Secondary
| Measure | Time frame |
|---|---|
| Repetitive Behavior Scale-Revised(RBS-R), Clinical Global Impression of Change(CGI-C), Vineland Adaptive Behavior Scales Second Edition(Vineland-II) the level of plasma glutamic acid,pro-BDNF,mature-BDNF,MMP-9,oxytocin [Time Frame:Change between baseline scores and 4-weeks] | — |
Countries
Japan
Contacts
Public ContactAyumi Okato
Chiba University Hospital Department of Child Psychiatry
Outcome results
None listed